Capricor Therapeutics, Inc. (CAPR)

NasdaqGS: CAPR · 实时价格 · USD

8.37

+0.07 (0.84%)

收盘价： Sep 11, 2026, 3:59 PM

8.37

+0.00%

盘后: 7:53 PM

提醒

Alert

股价、关键数字和最新消息，都在这一页。

0.84% (1D)

买价	6.14
市值	487M
营收（TTM）	n/a
净利润（TTM）	-129M
	0.72
	-2.45
	n/a
	-5.66
市净率（TTM）	1.98
市销率（TTM）	0.00
财报日期	Nov 10, 2026

卖价	10.66
成交量	2,070,244
20日均量	6,393,727
开盘价	8.32
前收盘价	8.30
日内区间	8.26 - 8.67
52周区间	2.96 - 40.37
分析师	买入
目标价	26.5 (216.61%)
分红	n/a
除息日	n/a

关于 CAPR

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome prot...

[阅读更多]

行业 Biotechnology

板块 Healthcare

上市日期 Feb 13, 2007

员工人数 231

交易所 NasdaqGS

股票代码 CAPR

官网 https://www.capricor.com

公司完整简介

财务表现

2025年，Capricor Therapeutics的营收为0，较上一年的22.27M下降-100%。净利润为-105.04M，增长159.58%。

财务报表

分析师预测

根据4位分析师的评级，CAPR的平均评级为“Buy”。12个月目标价为26.5，较最新价格上涨空间216.61%。

股票预测

财报意外

Capricor Therapeutics 已于 Aug 13, 2026 发布季度财报：

营收为 $0 低于预期 $0, ， NaN% 同比增长.
每股收益为 -0.7 低于预期 -0.12, ， -32.08% 同比下滑.

下次财报发布时间

Capricor Therapeutics, Inc. 的下次财报预计于 Nov 10, 2026, 盘中。
分析师预计营收为 ... 升级

股价变动原因

新闻

6天前 · Zacks

CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?

Capricor shares jump in a month as positive phase III data and renewed FDA engagement revive hopes for deramiocel approval in DMD.

1周前 · Insider Monkey

Could New Long-Term Data Support Capricor’s Duchenne Therapy?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has gained another opportunity to make the case for deramiocel, its experimental cell therapy for Duchenne muscular dystrophy. The FDA extended its review by ...

1周前 · MT Newswires

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index adding 0.6% and

1周前 · InvestorsHub

Capricor Therapeutics shares rise 2.5% following August FDA update

Capricor Therapeutics (NASDAQ:CAPR) shares rose 2. 5% in pre-market trading to $10.

1周前 · Stocktwits

Why Is CAPR Stock Rising Today? Piper Sandler Says Risk-Reward Favors Owning Stock Into FDA Decision

Piper Sandler upgraded Capricor to ‘Overweight’ from ‘Neutral’ and sharply raised the price target to $25, a roughly 150% upside potential from current levels.

第 1 页，共 2 页

Capricor Therapeutics, Inc. (CAPR)